Generate:Biomedicines vs Isomorphic Labs (2026)
Both design molecules with generative and structural models, and both develop their own programs rather than selling software. Generate:Biomedicines, listed on Nasdaq and founded by Flagship Pioneering, designs protein therapeutics in a loop of generating, building, measuring and learning, with more than 42,000 proteins made and tested, and its Chroma model generates structures conditioned on desired properties. It is clinical stage. Isomorphic Labs, the Alphabet company behind AlphaFold 3 with Google DeepMind, runs its Drug Design Engine for structure prediction, pocket finding, binding affinity and antibody modeling through strategic collaborations, with no code, weights or method published. Generate's evidence runs through its own lab loop and clinic; Isomorphic's through benchmark results it reports.
- A generate, build, measure and learn loop with more than 42,000 proteins generated, built and tested.
- Chroma, a generative model for novel protein structures and sequences conditioned on desired properties.
- A clinical stage pipeline of protein therapeutics designed on the platform.
- A unified engine for protein ligand structure, pocket identification, binding affinity and antibody antigen modeling, described in February 2026.
- Reported benchmark gains, including more than double AlphaFold 3's accuracy on the least similar protein ligand cases.
- The team behind AlphaFold 3, released with Google DeepMind in 2024.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Generate:Biomedicines and Isomorphic Labs are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Generate:Biomedicines | Isomorphic Labs |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Founded | 2018 | 2021 |
| Headquarters | Somerville, MA | London, United Kingdom |
| Website | generatebiomedicines.com | isomorphiclabs.com |
Side by Side
Select any grade to read the note behind it.
Product updates
The latest logged changes from each vendor, newest first, each linked to its source.
Generate:Biomedicines
-
Model / architecture
Generate:Biomedicines described an agent harness its team built with Claude Code to design CAR T cell signaling domains, combining LLM reasoning with computational tools while scientists steered and inspected each design.
Source
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Clinical stage generative biology company in Somerville, Massachusetts (Nasdaq: GENB), founded in 2018 by Flagship Pioneering, that designs protein therapeutics with machine learning rather than discovering them from natural scaffolds.
Source: AI Health Index, September 2026
Isomorphic Labs is a London based AI drug design company founded in 2021 by Sir Demis Hassabis, who leads it as chief executive. It was launched from DeepMind as an Alphabet company, and with Google DeepMind it released AlphaFold 3 in May 2024. Its Isomorphic Labs Drug Design Engine (IsoDDE), introduced in February 2026, joins proprietary models for protein ligand structure prediction, binding site discovery, binding affinity and antibody antigen modeling with generative agents that design molecules.
Source: AI Health Index, September 2026
Questions buyers ask
Which settings and specialties do Generate:Biomedicines and Isomorphic Labs cover?
For Generate:Biomedicines, the platform addresses protein therapeutics: antibodies against defined epitopes, functional antibodies that act on cell surface receptors, proteins optimized for arbitrary properties, and proteins recoded to reduce immune recognition.
With Isomorphic Labs, the internal pipeline focuses on oncology and immunology, while partnered work spans small molecules with Novartis and Eli Lilly and small molecules and biologics with Johnson & Johnson. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
What evidence is published for Generate:Biomedicines and Isomorphic Labs?
In Generate:Biomedicines' case, the method behind the designs is in the peer reviewed literature: Chroma in Nature, November 2023, with weights released for academic and non profit use. Collaborations with Amgen and Novartis cover confidential programs first announced in January 2022 and September 2024.
For Isomorphic Labs, the engine also predicted a recently discovered binding site on cereblon from the protein's sequence alone, and in a September 2026 example a design agent produced a molecule that modulated its target in laboratory testing. AlphaFold 3, the predecessor, appeared in peer reviewed form with Google DeepMind in 2024. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
Both records were reviewed on this site in September 2026. Isomorphic's benchmark figures are its own and cannot be checked without the method.
Ask both what share of designs work when made and tested, not only the best example.